4[1]HANAUSKE AR,CHEN V,PAOLETTI P,et al.Pemetrexed disodium:a novel antifolate clinically active against multiple solid tumors [J].Oncologist,2001,6(4):363-373.
5[2]ADJEI AA.Pemetrexed:a multitargeted antifolate agent with promising activity in solid tumors [J].Ann Oncol,2000,11(10):1335-1341.
6[3]SCHULTZ RM,PATEL VF,WORZALLA JF,et al.Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate,LY231514 [J].Anticancer Res,1999,19(1A):437-443.
7[4]TEICHER BA,CHEN V,SHIH C,et al.Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.[J].Clin Cancer Res,2000,6(3):1016-1023.
8[5]FOSSELLA FV,GATZEMEIER U.Phase I trials of pemetrexed [J].Semin Oncol,2002,29(2 Suppl 5):8-16.
9[6]RINALDI DA,KUHN JG,BURRIS HA,et al.A phase I evaluation of multitargeted antifolate (MTA,LY231514),administered every 21 days,utilizing the modified continual reassessment method for dose escalation [J].Cancer Chemother Pharmacol,1999,44(5):372-380.
10[7]THODTMANN R,DEPENBROCK H,DUMEZ,et al.Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin [J].J Clin Oncol,1999,17(10):3009-3016.
